Date: 2015-08-10
Type of information: Nomination
Compound:
Company: Khondrion (The Netherlands)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 10, 2015, Khondrion announced that Hans Schikan, former CEO of Prosensa, has joined Khondrion’s Advisory Board. Hans Schikan, PharmD, is an expert in drug development with a focus on rare genetic diseases. Until very recently he was CEO of Prosensa, which successfully completed an IPO on the US NASDAQ exchange in 2013 before being acquired by BioMarin early 2015. Hans Schikan is on the Boards of, amongst others, Prosensa Holding, Swedish Orphan Biovitrum, Hansa Medical, Wilson Therapeutics, Complix and the Core Team of the Top Sector Life Sciences & Health in The Netherlands. Before Prosensa he held various senior management positions at Organon and Genzyme. He has a PharmD from Utrecht University.
Financial terms:
Latest news:
